Oxford BioMedica plc  

(Public, LON:OXB)   Watch this stock  
Find more results for OXB
Dec 19 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 1.77 - 5.60
Open     -
Vol / Avg. 0.00/3.17M
Mkt cap 133.73M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 2.57B
Beta     -
Inst. own     -
Nov 21, 2014
Oxford BioMedica PLC Interim Management Statement (Estimated)

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -101.57% -206.44%
Operating margin -114.62% -238.57%
EBITD margin - -218.72%
Return on average assets -43.98% -58.30%
Return on average equity -57.70% -77.75%
Employees 95 -
CDP Score - -


The Oxford Science Park Medawar Centre Robert Robinson Avenue
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Oxford BioMedica plc (Oxford BioMedica) is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company is evaluating product candidates for four ocular indications, including uveitis and three undisclosed genetic retinal diseases. The Company's technology platform includes a LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a tumour antigen (5T4), which is a target for anti-cancer therapy. Its partnership with Sanofi comprises four LentiVector platform product candidates for four ocular indications: RetinoStat for wet age-related macular degeneration (AMD), StarGen for Stargardt disease, UshStat for Usher syndrome type 1B, and EncorStat for corneal graft rejection. Its manufacturing capabilities cover the entire product lifecycle; from pre-clinical development, to regulatory support, to all future stages of viral vector product clinical development.

Officers and directors

John Dawson Chief Executive Officer, Executive Director
Age: 54
Tim Watts Chief Financial Officer, Company Secretary, Executive Director
Age: 56
Peter Nolan Senior Vice President - Commercial Development, Executive Director
Age: 60
Paul Blake M.D. Chief Development Officer, Director
Age: 66
Nicholas Rodgers Non-Executive Independent Chairman of the Board
Age: 55
Andrew J. Heath M.D., Ph.D. Non-Executive Deputy Chairman of the Board, Senior Independent Director
Age: 64
Martin Diggle Non-Executive Director
Age: 52